Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals, Inc. (EPRX)
:EPRX
RESEARCH TOOLSreports
Total Valuation
Eupraxia Pharmaceuticals has a market cap or net worth of $143.29M. The enterprise value is $56.20M.
Market Cap$143.29M
Enterprise Value$56.20M
Share Statistics
Eupraxia Pharmaceuticals has 35,849,354 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding35,849,354
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Eupraxia Pharmaceuticals’s return on equity (ROE) is -1.05 and return on invested capital (ROIC) is -115.56%.
Return on Equity (ROE)-1.05
Return on Assets (ROA)-1.00
Return on Invested Capital (ROIC)-115.56%
Return on Capital Employed (ROCE)-1.16
Revenue Per Employee0.00
Profits Per Employee-780.14K
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eupraxia Pharmaceuticals is -3.04. Eupraxia Pharmaceuticals’s PEG ratio is 0.12.
PE Ratio-3.04
PS Ratio0.00
PB Ratio5.48
Price to Fair Value3.18
Price to FCF-3.69
Price to Operating Cash Flow-3.75
PEG Ratio0.12
Income Statement
In the last 12 months, Eupraxia Pharmaceuticals had revenue of 0.00 and earned -34.94M in profits. Earnings per share was -1.03.
Revenue0.00
Gross Profit-235.25K
Operating Income-36.99M
Pretax Income-35.27M
Net Income-34.94M
EBITDA-33.72M
Earnings Per Share (EPS)-1.03
Cash Flow
In the last 12 months, operating cash flow was -29.88M and capital expenditures -266.48K, giving a free cash flow of -30.14M billion.
Operating Cash Flow-29.88M
Free Cash Flow-30.14M
Free Cash Flow per Share-0.84
Dividends & Yields
Eupraxia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change45.39%
50-Day Moving Average3.70
200-Day Moving Average3.25
Relative Strength Index (RSI)50.35
Average Volume (3m)15.14K
Important Dates
Eupraxia Pharmaceuticals upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Eupraxia Pharmaceuticals as a current ratio of 11.10, with Debt / Equity ratio of 82.03%
Current Ratio11.10
Quick Ratio11.10
Debt to Market Cap<0.01
Net Debt to EBITDA0.98
Interest Coverage Ratio-28.15
Taxes
In the past 12 months, Eupraxia Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
Eupraxia Pharmaceuticals EV to EBITDA ratio is -2.17, with an EV/FCF ratio of -2.44.
EV to Sales0.00
EV to EBITDA-2.17
EV to Free Cash Flow-2.44
EV to Operating Cash Flow-2.44
Balance Sheet
Eupraxia Pharmaceuticals has $27.45M in cash and marketable securities with C$52.77K in debt, giving a net cash position of -$27.40M billion.
Cash & Marketable Securities$27.45M
Total DebtC$52.77K
Net Cash-$27.40M
Net Cash Per Share-$0.76
Tangible Book Value Per Share$0.90
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eupraxia Pharmaceuticals is $11.99, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.99
Price Target Upside210.62% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―